美国成年人使用他类药物和糖尿病病之间的关联:来自NHANES 2005 - 2018年的数据
Jinjing Guo1, Zhibing Jiang1, Yiping Xia1
1Medical School, Hunan University of Chinese Medicine, Changsha, Hunan, China.
Frontiers in endocrinology
|May 10, 2024
概括
长期使用他类药物,特别是与simvastatin一起使用,显著增加糖尿病病 (DN) 的风险. 这一发现强调了在为糖尿病管理处方他类药物时需要谨慎.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病病 (DN) 是一种严重的糖尿病并发症.
- 类药物通常用于DN治疗,但它们的效果仍在争论中.
- 了解DN因素对于患者的生活质量至关重要.
研究的目的:
- 调查他类药物使用与糖尿病病之间的关联.
- 分析他类药物持续时间和类型对DN风险的影响.
- 开发DN风险的预测模型.
主要方法:
- 使用了国家健康和营养检查调查 (NHANES) 数据.
- 采用加权多变量逻辑回归和分层分析.
- 开发了一个名图和ROC曲线用于DN风险预测.
主要成果:
- 静止剂使用显著增加了DN发病率 (OR=1.405).
- 较长的他类药物持续时间 (5-7年) 显示DN风险更高.
- 西姆瓦斯塔丁的使用与更高的DN发病率相关 (OR=1.448).
结论:
- 长期使用他类药物治疗与糖尿病病风险增加有关.
- 建议在长期使用阿托瓦斯塔丁和西姆瓦斯塔丁时谨慎使用.
- 需要进一步的研究来澄清他类药物在DN中的作用.
更多相关视频
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
652
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
652
Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
Diabetes: Symptoms, Diagnosis, and Complications
526
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
526
Oral Hypoglycemic Agents: Biguanides and Glitazones
192
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
192
Antihypertensive Drugs: Direct Renin Inhibitors
601
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
601
Renal Failure: Dose Adjustments
85
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
85


